VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy.

Department of Neurology, Mail Stop B182, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 8026, USA.
Neurology (Impact Factor: 8.3). 02/2005; 64(1):21-5. DOI: 10.1212/01.WNL.0000148484.19070.4D
Source: PubMed

ABSTRACT Two serious complications of varicella-zoster virus (VZV) reactivation are vasculopathy and postherpetic neuralgia (PHN). Clinical-virologic analyses have proven that VZV vasculopathy is caused by chronic active virus infection in cerebral arteries. Conclusive evidence that PHN is caused by persistent or productive VZV infection is less compelling because human ganglia are not accessible during life for pathologic and virologic examination. However, the notion that PHN may reflect a smoldering VZV ganglionitis is supported by 1) the detection of VZV DNA and proteins in peripheral blood mononuclear cells of many patients with PHN; 2) studies of multiple patients with zoster sine herpete, which indicate a productive VZV ganglionitis; and 3) a favorable response of some patients with zoster sine herpete and PHN to antiviral treatment. Few studies have used antiviral therapy to manage PHN with conflicting results. Larger, double-blind studies, which give IV antiviral drug, are needed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: This study determined the risk of acute coronary syndrome (ACS) associated with herpes zoster infection. We used the Taiwan National Health Insurance Research database (NHRID) to identify 57958 patients newly diagnosed with herpes zoster between 1999 and 2010; 231832 patients without herpes zoster were examined as the comparison group. Both cohorts were followed up until the end of 2010 to measure the incidence of ACS. Cox proportional hazards regression and Kaplan-Meier analyses were used to measure the hazard ratios (HR) and the cumulative incidences of ACS, respectively. The incidence of ACS was 1.24-fold higher in the herpes zoster group than in the comparison group (36.8 vs 29.6 per 10000 person-y; 95% CI, 1.16-1.33). After adjusting for age, sex, and comorbidities, the HR of ACS for the herpes zoster group compared with the comparison group was 1.15 (95% CI, 1.07-1.24). Analysis by the time lag (≦3mo, ≦1yr, >1yr) showed that the incidence of ACS remained significantly higher in the herpes zoster group than in the comparison group with an adjusted HR of 1.10 (95% CI, 1.02-1.19) after the 1-year follow-up period. The Kaplan-Meier survival curve showed that the risk of ACS was significantly higher in the herpes zoster group than in the comparison group (P <.0001). Herpes zoster infection is associated with an increased risk of ACS. This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 12/2013; 170(5). DOI:10.1111/bjd.12768 · 3.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Recent information on epidemiology and management of post-herpetic neuralgia (PHN), a painful complication of zoster, is scarce.Methods This study was conducted at the Pain Clinic of the Policlinico Tor Vergata, Rome, Italy, on eighty-five immunocompetent patients with a clinical diagnosis of PHN. At enrollment (time 0, T0), the patients were interviewed by physicians to obtain demographic data and information about their zoster clinical history and underwent a blood test for VZV-DNA research. DN4 and SF-12 questionnaires were used to assess the neuropathic nature of pain and the overall health status, respectively. A one-year follow-up was planned for enrolled cases, who were visited at regular intervals of at least 3 months.ResultsAt T0 all the patients were at least 6 months from the episode of acute zoster and still presented with intense pain (mean VAS =6.7; mean DN4¿=¿5.7). Using antivirals within 72 hours from the rash onset was associated to a significant reduction of pain at T0 (p¿=¿0.006 vs untreated patients). Only 2.6% of patients treated with antivirals during acute zoster but 18.6% of the untreated ones presented with neuropathic pain at T12 (p =0.007), even though the two groups were similar at T0. VZV-DNA was found in 5 out of the 50 available blood samples. At the last follow-up visit, PCS and MCS scores of the PHN patients were found to be recovered over those of the historical age-matched healthy controls. Undesirable side effects of analgesic therapies were observed in 15.3 to 28.8% of the patients.Conclusions Patients who six months after acute zoster still have significant neuropathic pain, have a high probability of suffering from chronic pain in the subsequent months/years. The initial antiviral treatment has a significant impact on the pain. Current strategies of analgesic therapy are effective to achieve relief of pain in PHN patients, but they are burdened with heavy and undesirable side effects.
    BMC Infectious Diseases 11/2014; 14(1):556. DOI:10.1186/s12879-014-0556-6 · 2.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical features, pathologic changes, and immune repertoire in a remarkable case of chronic varicella-zoster virus (VZV) ganglioneuritis without rash are described.
    Neurology 11/2013; 82(1). DOI:10.1212/01.wnl.0000438228.48470.86 · 8.30 Impact Factor